JBM (Healthcare) Limited (2161.HK)

HKD 1.85

(0.0%)

EBITDA Summary of JBM (Healthcare) Limited

  • JBM (Healthcare) Limited's latest annual EBITDA in 2023 was 204.39 Million HKD , up 83.47% from previous year.
  • JBM (Healthcare) Limited's latest quarterly EBITDA in 2023 FY was N/A , up 83.47% from previous quarter.
  • JBM (Healthcare) Limited reported an annual EBITDA of 111.4 Million HKD in 2022, up 32.4% from previous year.
  • JBM (Healthcare) Limited reported an annual EBITDA of 84.14 Million HKD in 2021, down -26.52% from previous year.
  • JBM (Healthcare) Limited reported a quarterly EBITDA of N/A for 2023 FY, up 83.47% from previous quarter.
  • JBM (Healthcare) Limited reported a quarterly EBITDA of 95.61 Million HKD for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of JBM (Healthcare) Limited (2023 - 2017)

Historical Annual EBITDA of JBM (Healthcare) Limited (2023 - 2017)

Year EBITDA EBITDA Growth
2023 204.39 Million HKD 83.47%
2022 111.4 Million HKD 32.4%
2021 84.14 Million HKD -26.52%
2020 114.51 Million HKD 25.97%
2019 87.71 Million HKD -12.18%
2018 96.2 Million HKD 24.25%
2017 83.37 Million HKD 0.0%

Peer EBITDA Comparison of JBM (Healthcare) Limited

Name EBITDA EBITDA Difference
Pak Fah Yeow International Limited 150.4 Million HKD -35.898%
Grand Pharmaceutical Group Limited 2.96 Billion HKD 93.11%
Extrawell Pharmaceutical Holdings Limited -129.51 Million HKD 257.806%
Wai Yuen Tong Medicine Holdings Limited 113.79 Million HKD -79.608%
Qianhai Health Holdings Limited -50.22 Million HKD 506.916%
Lee's Pharmaceutical Holdings Limited 109.82 Million HKD -86.114%
Essex Bio-Technology Limited 418.37 Million HKD 51.147%
Tongfang Kontafarma Holdings Limited 76.63 Million HKD -166.713%
PuraPharm Corporation Limited -26.16 Million HKD 881.039%
SSY Group Limited 2.11 Billion HKD 90.334%
Jacobson Pharma Corporation Limited 429.92 Million HKD 52.459%
China Resources Pharmaceutical Group Limited 15.43 Billion HKD 98.675%